Dechra Pharmaceuticals PLC Director/PDMR Shareholding (3543A)
22 Septiembre 2022 - 9:43AM
UK Regulatory
TIDMDPH
RNS Number : 3543A
Dechra Pharmaceuticals PLC
22 September 2022
22 September 2022
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
Dechra Pharmaceuticals PLC announces that on 20 September 2022,
the following PDMRs acquired ordinary shares of 1p each in the
Company pursuant to awards granted to them on 6 September 2019
under the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the
LTIP). The vesting of the awards was subject to the achievement of
performance conditions which were satisfied to the extent that the
awards vested at 65.5%.
Name Capacity Shares Total beneficial Percentage
acquired shareholding following of issued share
this announcement capital
--------------- ---------- ---------- ------------------------ -----------------
Ian Page Director 22,981 415,369 0.37%
Paul Sandland Director 3,999 13,650 0.01%
Tony Griffin Director 7,194 40,657 0.04%
The Notification of Dealing Forms set out below are provided in
accordance with the requirements of the UK Market Abuse
Regulation.
Notification of Dealing Forms
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
----------------------------------- ----------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Director/PDMR
----------------------------------- ----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------------- ----------------------------------------
3. Details of the Issuer
-----------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
----------------------------------- ----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
----------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of the Ordinary Shares of 1 pence each
financial instrument
Identification code ISIN: GB0009633180
----------------------------------- ----------------------------------------
b) Nature of the transaction Acquisition of shares pursuant to the
Company's Long Term Incentive Plan
----------------------------------- ----------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBPNil Cost 22,981
----------------------------------- ----------------------- ---------------
d) Aggregated information
* Aggregate volume
N/A
* Price
----------------------------------- ----------------------------------------
e) Date of the transaction 2022.09.20
----------------------------------- ----------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------------- ----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
----------------------------------- ----------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Director/PDMR
----------------------------------- ----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------------- ----------------------------------------
3. Details of the Issuer
-----------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
----------------------------------- ----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
----------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of the Ordinary Shares of 1 pence each
financial instrument
Identification code ISIN: GB0009633180
----------------------------------- ----------------------------------------
b) Nature of the transaction Acquisition of shares pursuant to the
Company's Long Term Incentive Plan
----------------------------------- ----------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBPNil Cost 3,999
----------------------------------- ----------------------- ---------------
d) Aggregated information
* Aggregate volume
N/A
* Price
----------------------------------- ----------------------------------------
e) Date of the transaction 2022.09.20
----------------------------------- ----------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------------- ----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Tony Griffin
---------------------------------------- ----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------------
a) Position/status Director/PDMR
---------------------------------------- ----------------------------------------
b) Initial notification/ Initial Notification
amendment
---------------------------------------- ----------------------------------------
3. Details of the Issuer
----------------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
---------------------------------------- ----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
---------------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
---------------------------------------- ----------------------------------------
b) Nature of the Acquisition of shares pursuant to the
transaction Company's Long Term Incentive Plan
---------------------------------------- ----------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBPnil 7,194
---------------------------------------- ------------------- -------------------
d) Aggregated information
* Aggregate volume
N/A
* Price
---------------------------------------- ----------------------------------------
e) Date of the transaction 2022.09.20
---------------------------------------- ----------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------------------- ----------------------------------------
For further information,
please contact:
Melanie Hall, Company Secretary
Telephone: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. For more information
please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBSGDCBSDDGDD
(END) Dow Jones Newswires
September 22, 2022 10:43 ET (14:43 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
